IDEAYA and Pfizer Collaborate to Evaluate IDE196 + Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

 IDEAYA and Pfizer Collaborate to Evaluate IDE196 + Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

IDEAYA and Pfizer Collaborate to Evaluate IDE196 + Binimetinib in Solid Tumors Harboring GNAQ or GNA11 Hotspot Mutations

Shots:

  • The companies entered into a clinical trial collaboration and supply agreement to evaluate the combination of IDE196 + binimetinib for GNAQ or GNA11 hotspot mutated solid tumors, including MUM, CM & CRC. The study is expected to be initiated in mid-2020
  • The clinical study will assess whether inhibition of the MAP-Kinase pathway at two nodes will enhance the response rate, depth and durability of clinical benefit. The companies will form a JDC and shares result of clinical study
  • IDEAYA will sponsor the study while Pfizer will provide its binimetinib for the study. IDE196 is a PKC inhibitor and binimetinib is a MEK inhibitor for which Pfizer has exclusive rights in the US and Canada

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: IDEAYA

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post